Schmoeckel E
No ORCID on file
· 6 papers in corpus
· active 2018-2024
Top journals
Frequent coauthors
- Meister S 5
- Jeschke U 5
- Mayr D 4
- Badmann S 2
- Czogalla B 2
- Kolben T 2
- Hertlein L 2
- Hester A 2
- Fabian Trillsch 2
- Kuhn C 2
2024
ObjectivesThe chemokine CCL22 is recognized for recruiting immunosuppressive regulatory T-cells (Treg) that contribute to disease progression in various tumor entities helping them to evade the host immune response. Our study aims to identi…
2022
In recurrent epithelial ovarian cancer (EOC) most patients develop platinum-resistance. On molecular level the NRF2 pathway, a cellular defense mechanism against reactive oxygen species, is induced. In this study, we investigate AKR1C1/2, t…
2021
BackgroundFor young borderline ovarian tumor (BOT) patients, preservation of the uterus was incorporated as an accepted option into treatment guidelines. For the endometrioid subtype (eBOT) however, adequate histological evaluation is chall…
2020
PurposeThyroid hormone receptors (THR) have manifold functions and are involved in the carcinogenesis of several tumor types. Within this study, we aimed to investigate the expression pattern (nuclear versus cytoplasmic) of the THR alpha an…
2020
Prognostic factors are of great interest in patients with endometrial cancer. One potential factor could be the protein MSX1, a transcription repressor, that has an inhibitory effect on the cell cycle. For this study, endometrioid endometri…
2018
AimThe objective of this study was to evaluate the prognostic value of ARID1A, p53, p21, p16 and ß-Catenin in endometrioid and clear cell ovarian and endometrial carcinomas.Materials and methods97 tumors were available for analysis of ARID1…